216 related articles for article (PubMed ID: 24097984)
1. Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.
Takahashi M; Hasegawa Y; Ikeda Y; Wada Y; Tajiri M; Ariki S; Takamiya R; Nishitani C; Araki M; Yamaguchi Y; Taniguchi N; Kuroki Y
J Biol Chem; 2013 Nov; 288(46):32910-21. PubMed ID: 24097984
[TBL] [Abstract][Full Text] [Related]
2. The single N-glycan deletion mutant of soluble ErbB3 protein attenuates heregulin β1-induced tumor progression by blocking of the HIF-1 and Nrf2 pathway.
Takamiya R; Takahashi M; Uehara Y; Ariki S; Hashimoto J; Hasegawa Y; Kuroki Y
Biochem Biophys Res Commun; 2014 Nov; 454(3):364-8. PubMed ID: 25451255
[TBL] [Abstract][Full Text] [Related]
3. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
4. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ
J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028
[TBL] [Abstract][Full Text] [Related]
5. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
Vijapurkar U; Kim MS; Koland JG
Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
[TBL] [Abstract][Full Text] [Related]
6. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
7. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S; Hamburger AW
J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
[TBL] [Abstract][Full Text] [Related]
8. The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion.
Yokoe S; Takahashi M; Asahi M; Lee SH; Li W; Osumi D; Miyoshi E; Taniguchi N
Cancer Res; 2007 Mar; 67(5):1935-42. PubMed ID: 17332320
[TBL] [Abstract][Full Text] [Related]
9. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
Hutcheson IR; Goddard L; Barrow D; McClelland RA; Francies HE; Knowlden JM; Nicholson RI; Gee JM
Breast Cancer Res; 2011 Mar; 13(2):R29. PubMed ID: 21396094
[TBL] [Abstract][Full Text] [Related]
11. P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells.
Ratchford AM; Baker OJ; Camden JM; Rikka S; Petris MJ; Seye CI; Erb L; Weisman GA
J Biol Chem; 2010 Mar; 285(10):7545-55. PubMed ID: 20064929
[TBL] [Abstract][Full Text] [Related]
12. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
Yang C; Liu Y; Lemmon MA; Kazanietz MG
Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
[TBL] [Abstract][Full Text] [Related]
13. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
14. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
15. Akt-mediated survival of oligodendrocytes induced by neuregulins.
Flores AI; Mallon BS; Matsui T; Ogawa W; Rosenzweig A; Okamoto T; Macklin WB
J Neurosci; 2000 Oct; 20(20):7622-30. PubMed ID: 11027222
[TBL] [Abstract][Full Text] [Related]
16. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.
Bourguignon LY; Gilad E; Peyrollier K
J Biol Chem; 2007 Jul; 282(27):19426-41. PubMed ID: 17493932
[TBL] [Abstract][Full Text] [Related]
17. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.
Fitzpatrick VD; Pisacane PI; Vandlen RL; Sliwkowski MX
FEBS Lett; 1998 Jul; 431(1):102-6. PubMed ID: 9684874
[TBL] [Abstract][Full Text] [Related]
18. Heregulin enhances regenerative proliferation in postnatal rat utricular sensory epithelium after ototoxic damage.
Zheng JL; Frantz G; Lewis AK; Sliwkowski M; Gao WQ
J Neurocytol; 1999; 28(10-11):901-12. PubMed ID: 10900093
[TBL] [Abstract][Full Text] [Related]
19. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
20. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
